cisplatin + carboplatin + pemetrexed + gemcitabine + paclitaxel + docetaxel

This is a combination regimen comprising six cytotoxic chemotherapy agents: **cisplatin**, **carboplatin**, **pemetrexed**, **gemcitabine**, **paclitaxel**, and **docetaxel**. Each is a well-established antineoplastic drug with distinct but often overlapping mechanisms of action. Such a combination is highly unusual in clinical practice, as multi-agent chemotherapy regimens generally use only two or three drugs due to the risk of compounded toxicity. - **Cisplatin** and **carboplatin** are platinum-based agents that cause DNA cross-linking and inhibit DNA synthesis and function. - **Pemetrexed** is an antifolate that inhibits several enzymes involved in folate metabolism and DNA synthesis. - **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis. - **Paclitaxel** and **docetaxel** are taxanes that promote microtubule assembly while inhibiting disassembly, disrupting mitosis. All agents are primarily used in the treatment of solid tumors, especially lung cancer, but their combined use at this scale is not typical and may only be considered in palliative settings, trials, or experimental regimens if ever used.